Last reviewed: June 16, 2026

Last updated: June 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The weight loss medication landscape has expanded far beyond semaglutide alone. Today, patients have access to tirzepatide—which targets two peptide pathways instead of one—oral formulations, microdose protocols, and even dual-compound injections designed to maximize results. PlexusDx specializes in connecting patients with the right medication match through personalized genetic insights, ensuring treatment aligns with how your body naturally processes these compounds.

How Tirzepatide Works Differently Than Semaglutide

Semaglutide activates GLP-1 receptors to slow stomach emptying, reduce appetite, and improve blood sugar control. Tirzepatide takes a dual approach by targeting both GLP-1 and GIP receptors simultaneously. This combination mechanism produced weight loss results averaging 20–22% of body weight in clinical trials, compared to 15–18% with semaglutide alone at comparable doses.

The GIP receptor pathway influences how your body processes glucose and regulates energy expenditure independently from GLP-1 signaling. By engaging both pathways, tirzepatide may produce stronger satiety effects and more sustained metabolic changes. For patients whose bodies respond favorably to GIP activation—determined partly by genetic variants like GIPR rs1800437—tirzepatide often delivers faster results within the same time frame.

Oral Versus Injectable Medications: Delivery Method Considerations

Oral semaglutide and tirzepatide tablets offer convenience for patients who prefer avoiding injections, though they require specific administration protocols to optimize absorption. Tablets must be taken on an empty stomach with minimal water, and food or other medications can significantly reduce effectiveness. Injectable versions bypass digestive variability and deliver consistent doses directly into subcutaneous tissue, making them more predictable for dose escalation.

PlexusDx offers both oral and injectable options to accommodate lifestyle preferences. Compounded semaglutide injection starts at $149 per month, while oral semaglutide begins at $249 monthly—reflecting the added manufacturing complexity of oral formulations. Neither format changes pricing based on dose adjustments; PlexusDx maintains the same monthly cost as patients titrate upward, meaning your dose may increase but your price stays fixed.

Understanding GLP-Squared: Dual-Compound Injections for Personalized Results

PlexusDx's GLP-Squared Injection combines semaglutide and tirzepatide in a single weekly dose, allowing simultaneous activation of both GLP-1 and GIP pathways. This dual-compound approach addresses cases where monotherapy reaches a plateau or where individual genetic predispositions suggest synergistic benefit. GLP-Squared starts at $249 monthly and serves patients seeking maximum efficacy without managing multiple injections.

Genetic testing through PlexusDx's Precision Peptide Genetic Test identifies how efficiently your body activates key receptors like GLP1R rs6923761 and GIPR rs1800437. Patients with specific variants may respond more dramatically to dual-pathway activation than to single-agent therapy. This personalization eliminates guesswork and helps clinicians select between monotherapy, dual compounds, or microdose protocols based on your unique peptide metabolism.

Microdose GLP-1 Protocols and Emerging Alternatives

PlexusDx's Microdose GLP-1 Protocol ($129 monthly) offers lower-dose weekly injections designed for patients experiencing side effects from standard dosing or those seeking gentler metabolic support. Microdosing maintains appetite suppression while reducing nausea, vomiting, and gastrointestinal effects that sometimes lead to treatment discontinuation. Clinical experience suggests microdose approaches work best for individuals with lower body weight, older age, or genetic variants indicating heightened receptor sensitivity.

Beyond semaglutide and tirzepatide, emerging research explores other peptide-based therapies, though PlexusDx currently focuses on these two proven agents available through licensed 503A compounding pharmacies. The advantage of compounded medications is access without insurance requirements, HSA/FSA eligibility, and flat monthly pricing—making consistency and affordability predictable from month one. No membership fees or hidden charges apply; all 50 states are served with direct delivery to your home.

Cost Comparison and Access: Why Compounded Medications from PlexusDx

Brand-name Ozempic, Saxenda, and Zepbound often carry high out-of-pocket costs even with insurance, and prior authorization delays are common. PlexusDx compounded semaglutide injection ($149/mo) and tirzepatide injection ($249/mo) bypass these barriers by sourcing from licensed 503A compounding pharmacies, which offer cost transparency and immediate access. Patients begin therapy within days rather than weeks, and dosing flexibility allows clinicians to adjust strength without price increases.

The Precision Peptide Genetic Test ($99 add-on after the first month) maps 14 metabolic pathways and 150+ genetic insights to predict medication response before escalating doses. This test identifies predispositions in genes like FTO rs9939609 and MC4R rs17782313, informing whether semaglutide, tirzepatide, GLP-Squared, or microdose protocols align best with your physiology. Personalized selection reduces trial-and-error cycles and accelerates time to optimal dose.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between semaglutide and tirzepatide?

Semaglutide activates only GLP-1 receptors, while tirzepatide activates both GLP-1 and GIP receptors simultaneously. This dual-pathway action in tirzepatide often produces stronger appetite suppression and greater weight loss in clinical trials. PlexusDx offers both compounds starting at $149/month (semaglutide injection) and $249/month (tirzepatide injection), with pricing fixed regardless of dose adjustments.

Can I switch from semaglutide to tirzepatide if I'm not seeing results?

Yes, switching between medications is a common clinical strategy when response plateaus or remains suboptimal after 8–12 weeks. PlexusDx clinicians can transition you from semaglutide to tirzepatide or recommend GLP-Squared (the dual-compound option) based on your genetics and tolerance profile. The Precision Peptide Genetic Test predicts which pathway your body activates most efficiently, guiding this decision before switching.

How much does PlexusDx treatment cost and what's included?

PlexusDx compounded semaglutide injection starts at $149/month, tirzepatide injection at $249/month, and GLP-Squared dual-compound at $249/month. Oral formulations cost more due to manufacturing complexity. Pricing is flat per month regardless of dose—your dose may increase, but your price won't. Genetic testing is a $99 add-on after your first month, and HSA/FSA funds are accepted. No insurance required, no membership fees, and all 50 states are served.

Are compounded GLP-1 medications as safe as brand-name versions?

PlexusDx medications come from licensed 503A compounding pharmacies, which follow strict FDA quality and sterility standards identical to brand manufacturers. While compounded versions are not FDA-approved (brand versions are), they contain the same active ingredient and undergo rigorous testing. Side effect profiles are comparable to brand medications, and clinicians monitor your response closely during treatment initiation and dose escalation.

How can genetic testing help me choose the right weight loss medication?

The Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence how efficiently your body activates these receptors and processes appetite signals. Patients with specific GIPR variants may respond dramatically better to tirzepatide's dual-pathway approach, while others optimize with semaglutide alone. This personalization eliminates guesswork and helps PlexusDx clinicians select semaglutide, tirzepatide, GLP-Squared, or microdose protocols aligned with your unique genetics.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves